c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
Produits appartenant à la catégorie "c-Met/HGFR"
Trier par
Canlitinib
CAS :Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61SRI 31215 TFA
CAS :SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Formule :C27H34F3N5O3Degré de pureté :98.25% - 99.97%Couleur et forme :SolidMasse moléculaire :533.6Ref: TM-T5478
1mg43,00€5mg96,00€10mg135,00€25mg261,00€50mg391,00€100mg557,00€200mg753,00€1mL*10mM (DMSO)101,00€1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofDegré de pureté :98%Couleur et forme :Odour SolidCEP-40783
CAS :CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).Formule :C31H26F2N4O6Degré de pureté :99.45% - 99.64%Couleur et forme :SolidMasse moléculaire :588.56Merestinib
CAS :Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Formule :C30H22F2N6O3Degré de pureté :95% - 99.56%Couleur et forme :SolidMasse moléculaire :552.53Ref: TM-T3455
1mg49,00€2mg70,00€5mg105,00€10mg144,00€25mg254,00€50mg424,00€100mg605,00€500mg1.264,00€1mL*10mM (DMSO)126,00€PF-04217903
CAS :MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formule :C19H16N8ODegré de pureté :98.41% - 98.55%Couleur et forme :SolidMasse moléculaire :372.38Ref: TM-T2676
1mg38,00€2mg49,00€5mg73,00€10mg97,00€25mg172,00€50mg288,00€100mg520,00€1mL*10mM (DMSO)79,00€Afatinib
CAS :Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Formule :C24H25ClFN5O3Degré de pureté :97.56% - 99.9%Couleur et forme :Off-White SolidMasse moléculaire :485.94Ref: TM-T21312
5mg35,00€10mg51,00€25mg86,00€50mg115,00€100mg144,00€200mg177,00€500mg300,00€1mL*10mM (DMSO)52,00€PROTAC c-Met degrader-1
CAS :PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formule :C45H41FN10O5Couleur et forme :SolidMasse moléculaire :820.87Onartuzumab
CAS :Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Degré de pureté :97.3%Couleur et forme :LiquidMasse moléculaire :146.99 kDaEmibetuzumab
CAS :Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Degré de pureté :SDS-PAGE:96.2%;SEC-HPLC:98.8%Couleur et forme :LiquidMasse moléculaire :143.74 kDaCabozantinib
CAS :Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).Formule :C28H24FN3O5Degré de pureté :99.59% - 99.88%Couleur et forme :SolidMasse moléculaire :501.51Crizotinib hydrochloride
CAS :Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Formule :C21H23Cl3FN5ODegré de pureté :98.73% - 98.87%Couleur et forme :SolidMasse moléculaire :486.8Ref: TM-T8399
5mg37,00€10mg52,00€25mg82,00€50mg99,00€100mg138,00€200mg171,00€500mg227,00€1mL*10mM (DMSO)59,00€c-met-IN-1
CAS :c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Formule :C35H37FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.7Hepln-13
CAS :Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formule :C17H13BrN2Degré de pureté :97.67%Couleur et forme :SolidMasse moléculaire :325.2Ref: TM-T25492
1mg38,00€2mg50,00€5mg85,00€10mg126,00€25mg245,00€50mg364,00€100mg507,00€200mg700,00€1mL*10mM (DMSO)96,00€Crizotinib
CAS :Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formule :C21H22Cl2FN5ODegré de pureté :99% - 99.87%Couleur et forme :SolidMasse moléculaire :450.34Narnatumab
CAS :Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.Couleur et forme :LiquidSYN1143
CAS :SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formule :C31H29FN4O5Degré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :556.58SU11274
CAS :SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formule :C28H30ClN5O4SDegré de pureté :98.62% - 99.44%Couleur et forme :Orange PowderMasse moléculaire :568.09Ref: TM-T6154
1mg47,00€2mg59,00€5mg97,00€10mg150,00€25mg283,00€50mg465,00€100mg688,00€1mL*10mM (DMSO)150,00€SAR125884 hydrochlorid (1116743-46-4(free base))
CAS :SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587Ref: TM-T5677
1mg38,00€5mg60,00€10mg90,00€25mg188,00€50mg279,00€100mg395,00€200mg567,00€1mL*10mM (DMSO)101,00€Glumetinib
CAS :Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).Formule :C21H17N9O2SDegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :459.48Tyrosine kinase-IN-6
CAS :Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].Formule :C37H31F2N5O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :695.73SGX-523
CAS :SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.Formule :C18H13N7SDegré de pureté :100% - 99.49%Couleur et forme :SolidMasse moléculaire :359.41Glesatinib
CAS :Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H27F2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.7Tivantinib
CAS :Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Formule :C23H19N3O2Degré de pureté :98% - 99.41%Couleur et forme :SolidMasse moléculaire :369.42S49076
CAS :S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formule :C22H22N4O4SDegré de pureté :95.35% - 97.4%Couleur et forme :SolidMasse moléculaire :438.5Ref: TM-T3274
1mg47,00€2mg63,00€5mg84,00€10mg96,00€25mg170,00€50mg305,00€100mg558,00€1mL*10mM (DMSO)92,00€DS-1205
CAS :DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formule :C41H42FN5O7Degré de pureté :99.28%Couleur et forme :SolidMasse moléculaire :735.8X-376
CAS :X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Formule :C25H25Cl2FN6O3Degré de pureté :97.87%Couleur et forme :SolidMasse moléculaire :547.41Ref: TM-T3550
1mg35,00€2mg50,00€5mg87,00€10mg119,00€25mg258,00€50mg427,00€100mg582,00€1mL*10mM (DMSO)105,00€Amuvatinib
CAS :Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Formule :C23H21N5O3SDegré de pureté :98.48% - 99.54%Couleur et forme :SolidMasse moléculaire :447.51KRC-00715
CAS :KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.Formule :C25H25F3N8O3Couleur et forme :SolidMasse moléculaire :542.51AMG-458
CAS :AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Formule :C30H29N5O5Degré de pureté :99.77% - 99.91%Couleur et forme :SolidMasse moléculaire :539.58c-Kit-IN-1
CAS :c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).Formule :C26H21F2N5O3Degré de pureté :98.16% - 98.72%Couleur et forme :SolidMasse moléculaire :489.47Ref: TM-T4332
1mg46,00€2mg59,00€5mg87,00€10mg144,00€25mg304,00€50mg542,00€100mg778,00€500mg1.605,00€1mL*10mM (DMSO)94,00€c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Formule :C21H15FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.37Umikibart
Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.Couleur et forme :Odour Liquidc-Met-IN-26
CAS :c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formule :C24H19F2N9Couleur et forme :SolidMasse moléculaire :471.46BMS-777607
CAS :BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formule :C25H19ClF2N4O4Degré de pureté :98.16% - 98.30%Couleur et forme :SolidMasse moléculaire :512.89Ref: TM-T2658
2mg63,00€5mg90,00€10mg142,00€25mg265,00€50mg409,00€100mg727,00€200mg1.091,00€500mg1.636,00€BMS817378
CAS :BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Formule :C24H18ClF2N4O7PDegré de pureté :100%Couleur et forme :SolidMasse moléculaire :578.85Cabozantinib hydrochloride
CAS :Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :537.96Ref: TM-T5164
1mg44,00€2mg55,00€5mg69,00€10mg97,00€25mg169,00€50mg248,00€100mg349,00€200mg568,00€500mg908,00€c-Met-IN-19
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,Formule :C34H37Cl2FN4O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :735.65Davutamig
CAS :Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Degré de pureté :98%Couleur et forme :LiquidPF-04217903 methanesulfonate
CAS :PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formule :C20H20N8O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.49Golvatinib
CAS :Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormule :C33H37F2N7O4Degré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :633.69MK-8033
CAS :MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formule :C25H21N5O3SDegré de pureté :97.16%Couleur et forme :SolidMasse moléculaire :471.53MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Formule :C26H23N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :449.51Ningetinib
CAS :Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formule :C31H29FN4O5Degré de pureté :99.77% - 99.95%Couleur et forme :SolidMasse moléculaire :556.58PHA-665752
CAS :PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formule :C32H34Cl2N4O4SDegré de pureté :97.01% - 99.35%Couleur et forme :SolidMasse moléculaire :641.61MGCD-265 analog
CAS :Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Formule :C26H20FN5O2S2Degré de pureté :98.06% - 98.68%Couleur et forme :SolidMasse moléculaire :517.6AMG-208
CAS :AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formule :C22H17N5O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :383.4Tepotinib hydrochloride(1 : x)
CAS :Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14Formule :C29H29ClN6O2Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :529.04Capmatinib 2HCl
CAS :Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formule :C23H19Cl2FN6ODegré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :485.34Ref: TM-T4260
1mg44,00€2mg55,00€5mg70,00€10mg87,00€25mg145,00€50mg258,00€100mg430,00€500mg998,00€1mL*10mM (DMSO)97,00€c-Met inhibitor 1
CAS :c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formule :C17H14N8SDegré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :362.41Ref: TM-T10655
1mg85,00€5mg172,00€10mg236,00€25mg398,00€50mg588,00€100mg838,00€1mL*10mM (DMSO)188,00€
